日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Antibody characterization is critical to enhance reproducibility in biomedical research

抗体表征对于提高生物医学研究的可重复性至关重要

Richard A Kahn, Harvinder Virk, Carl Laflamme, Douglas W Houston, Nicole K Polinski, Rob Meijers, Allan I Levey, Clifford B Saper, Timothy M Errington, Rachel E Turn, Anita Bandrowski, James S Trimmer, Meghan Rego, Leonard P Freedman, Fortunato Ferrara, Andrew R M Bradbury, Hannah Cable, Skye Longwo

First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

针对难治性实体瘤的抗核心1 O-聚糖靶向单克隆抗体NEO-201的首次人体1期临床试验

Cole, Christopher B; Morelli, Maria Pia; Fantini, Massimo; Miettinen, Markku; Fetsch, Patricia; Peer, Cody; Figg, William D; Yin, Tyler; Houston, Nicole; McCoy, Ann; Lipkowitz, Stanley; Zimmer, Alexandra; Lee, Jung-Min; Pavelova, Miroslava; Villanueva, Erin N; Trewhitt, Kathryn; Solarz, B Brooke; Fergusson, Maria; Mavroukakis, Sharon A; Zaki, Anjum; Tsang, Kwong Y; Arlen, Philip M; Annunziata, Christina M

Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors

更正:针对难治性实体瘤的抗核心1 O-聚糖靶向单克隆抗体NEO-201的首次人体1期临床试验

Cole, Christopher B; Morelli, Maria Pia; Fantini, Massimo; Miettinen, Markku; Fetsch, Patricia; Peer, Cody; Figg, William D; Yin, Tyler; Houston, Nicole; McCoy, Ann; Lipkowitz, Stanley; Zimmer, Alexandra; Lee, Jung-Min; Pavelova, Miroslava; Villanueva, Erin N; Trewhitt, Kathryn; Solarz, B Brooke; Fergusson, Maria; Mavroukakis, Sharon A; Zaki, Anjum; Tsang, Kwong Y; Arlen, Philip M; Annunziata, Christina M

Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases

T-DM1 和节拍式替莫唑胺用于 HER2 阳性乳腺癌脑转移二级预防的 I 期研究和无细胞 DNA 分析

Jenkins, Sarah; Zhang, Wei; Steinberg, Seth M; Nousome, Darryl; Houston, Nicole; Wu, Xiaolin; Armstrong, Terri S; Burton, Eric; Smart, Dee Dee; Shah, Ritu; Peer, Cody J; Mozarsky, Brett; Arisa, Oluwatobi; Figg, William D; Mendoza, Tito R; Vera, Elizabeth; Brastianos, Priscilla; Carter, Scott; Gilbert, Mark R; Anders, Carey K; Connolly, Roisín M; Tweed, Carol; Smith, Karen L; Khan, Imran; Lipkowitz, Stanley; Steeg, Patricia S; Zimmer, Alexandra S

A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

ONC201治疗复发/难治性转移性乳腺癌和晚期子宫内膜癌的单臂、开放标签II期研究

Atkins, Sarah L P; Greer, Yoshimi Endo; Jenkins, Sarah; Gatti-Mays, Margaret E; Houston, Nicole; Lee, Sunmin; Lee, Min-Jung; Rastogi, Shraddha; Sato, Nahoko; Burks, Christina; Annunziata, Christina M; Lee, Jung-Min; Nagashima, Kunio; Trepel, Jane B; Lipkowitz, Stanley; Zimmer, Alexandra S

Linkage-specific ubiquitin chain formation depends on a lysine hydrocarbon ruler

连接特异性泛素链的形成依赖于赖氨酸烃标尺

Joanna Liwocha #, David T Krist #, Gerbrand J van der Heden van Noort #, Fynn M Hansen, Vinh H Truong, Ozge Karayel, Nicholas Purser, Daniel Houston, Nicole Burton, Mark J Bostock, Michael Sattler, Matthias Mann, Joseph S Harrison, Gary Kleiger, Huib Ovaa, Brenda A Schulman1

Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

替莫唑胺在HER2阳性乳腺癌脑转移二级预防中的应用

Zimmer, Alexandra S; Steinberg, Seth M; Smart, Dee Dee; Gilbert, Mark R; Armstrong, Terri S; Burton, Eric; Houston, Nicole; Biassou, Nadia; Gril, Brunilde; Brastianos, Priscilla K; Carter, Scott; Lyden, David; Lipkowitz, Stanley; Steeg, Patricia S

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses

一项针对复发性女性癌症的 I 期研究,评估了 PD-L1 抑制剂度伐利尤单抗联合 PARP 抑制剂奥拉帕尼和 VEGFR1-3 抑制剂西地尼布的疗效,并进行了生物标志物分析。

Zimmer, Alexandra S; Nichols, Erin; Cimino-Mathews, Ashley; Peer, Cody; Cao, Liang; Lee, Min-Jung; Kohn, Elise C; Annunziata, Christina M; Lipkowitz, Stanley; Trepel, Jane B; Sharma, Rajni; Mikkilineni, Lekha; Gatti-Mays, Margaret; Figg, William D; Houston, Nicole D; Lee, Jung-Min

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron(®) (Peginterferon alfa-2b) and Actimmune(®) (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

一项针对复发性卵巢癌的I期临床试验,研究了体外用Sylatron®(聚乙二醇干扰素α-2b)和Actimmune®(干扰素γ-1b)刺激的自体单核细胞腹腔内给药的疗效。

Green, Daniel S; Nunes, Ana T; David-Ocampo, Virginia; Ekwede, Irene B; Houston, Nicole D; Highfill, Steven L; Khuu, Hanh; Stroncek, David F; Steinberg, Seth M; Zoon, Kathryn C; Annunziata, Christina M

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

程序性死亡配体 1 抑制剂度伐利尤单抗联合聚(ADP-核糖)聚合酶抑制剂奥拉帕尼或血管内皮生长因子受体 1-3 抑制剂西地尼布治疗女性癌症的安全性和临床活性:一项剂量递增的 I 期研究

Lee, Jung-Min; Cimino-Mathews, Ashley; Peer, Cody J; Zimmer, Alexandra; Lipkowitz, Stanley; Annunziata, Christina M; Cao, Liang; Harrell, Maria I; Swisher, Elizabeth M; Houston, Nicole; Botesteanu, Dana-Adriana; Taube, Janis M; Thompson, Elizabeth; Ogurtsova, Aleksandra; Xu, Haiying; Nguyen, Jeffers; Ho, Tony W; Figg, William D; Kohn, Elise C